Cd44 pe cyanine 7

Manufactured by BioLegend

CD44-PE/Cyanine 7 is a fluorochrome-conjugated antibody that specifically binds to the CD44 antigen. CD44 is a cell surface glycoprotein involved in cell-cell interactions, cell adhesion, and migration. The PE/Cyanine 7 fluorochrome allows for the detection and analysis of CD44-expressing cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

CD44-PE (36 citations)

3 protocols using cd44 pe cyanine 7

T Cell Phenotyping for SARS-CoV-2 Immunity

Check if the same lab product or an alternative is used in the 5 most similar protocols

For T cell analysis, single cell suspensions were incubated with FcγR antibody (clone 93, BioLegend) to block non-specific antibody binding, followed by staining with a cocktail of labeled mAbs including Fixable Viability dye eFluor506, CD3e-BV711 (1:100, clone:145–2C11, BD Biosciences), CD8α-PerCP/Cyanine 5.5 (1:100, 53–6.7, BioLegend), CD4-BV785 (1:100, clone: RM4–5, BioLegend), CD44-PE/Cyanine 7 (1:100, clone: IM7, BioLegend), CD69-FITC (1:100, clone: H1.2F3, BioLegend), CD103-PE (1:100, clone: 2E7, BioLegend) and APC-labeled SARS-CoV-2 S- specific tetramer (MHC class I tetramer, residues 539–546, VNFNFNGL, H-2K(B) for 60 min at room temperature. Cells were washed twice with FACS buffer, fixed with 2% paraformaldehyde (PFA) for 20 min prior to data acquisition. Data were acquired on an Aurora (Cytek) spectral flow cytometer and analyzed in FlowJo v10 software.

Ying B., Darling T.L., Desai P., Liang C.Y., Dmitriev I.P., Soudani N., Bricker T., Kashentseva E.A., Harastani H., Schmidt A.G., Curiel D.T., Boon A.C, & Diamond M.S. (2023). A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters. bioRxiv.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

TNF‐α‐Brilliant Violet 421 (BioLegend, Cat.# 506328, clone: MP6‐XT22, 1:80), FOXP3‐eFluor 450 (eBioscience, Cat.# 48‐5773‐82, clone: FJK‐16s, 1:300), IL‐2‐Brilliant Violet 711 (BioLegend, Cat.# 503837, clone: JES6‐5H4, 1:40), IFN‐ɣ‐Brilliant Violet 785 (BioLegend, Cat.# 505838, clone: XMG1.2, 1:80), CD8a‐FITC (BioLegend, Cat.# 100706, clone: 53‐6.7, 1:50), CD4‐PerCP‐Cy5.5 (BioLegend, Cat.# 100434, clone: GK1.5, 1:80), CD25‐PE/Cy5 (BioLegend, Cat.# 102010, clone: PC61, 1:80), CD44‐PE/Cyanine7 (BioLegend, Cat.# 103029, clone: IM7, 1:80), IL‐10‐APC (BioLegend, Cat.# 505010, clone: JES5‐16E3, 1:80), CD107b‐Alexa Fluor 647 (BioLegend, Cat.# 108512, clone: M3/84, 1:200), CD3‐APC/Cyanine7 (BioLegend, Cat.# 100222, clone: 17A2, 1:80), and LIVE/DEAD Fixable Yellow Dead Cell Stain (Thermo Fisher Scientific, Cat.# L34967, 1:7500).

Matos A.I., Peres C., Carreira B., Moura L.I., Acúrcio R.C., Vogel T., Wegener E., Ribeiro F., Afonso M.B., Santos F.M., Martínez‐Barriocanal Á., Arango D., Viana A.S., Góis P.M., Silva L.C., Rodrigues C.M., Graca L., Jordan R., Satchi‐Fainaro R, & Florindo H.F. (2023). Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors. Advanced Science, 10(25), 2300299.

+ Open protocol

+ Expand

Multiparametric T Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

For T cell analysis, single-cell suspensions were incubated with FcγR antibody (clone 93, BioLegend) to block non-specific antibody binding, followed by staining with a cocktail of labeled monoclonal antibodies, including Fixable Viability dye eFluor506, CD3e-BV711 (1:100, clone 145-2C11, BD Biosciences), CD8α-PerCP/Cyanine 5.5 (1:100, 53-6.7, BioLegend), CD4-BV785 (1:100, clone RM4-5, BioLegend), CD44-PE/Cyanine 7 (1:100, clone IM7, BioLegend), CD69-FITC (1:100, clone H1.2F3, BioLegend), CD103-PE (1:100, clone 2E7, BioLegend) and APC-labeled SARS-CoV-2 S-specific tetramer (MHC class I tetramer, residues 539–546, VNFNFNGL, H-2K^b) for 60 min at room temperature. Cells were washed twice with FACS buffer and fixed with 2% paraformaldehyde for 20 min before data acquisition. Data were acquired on an Aurora (Cytek) spectral flow cytometer and analyzed with FlowJo v10 software.

Ying B., Darling T.L., Desai P., Liang C.Y., Dmitriev I.P., Soudani N., Bricker T., Kashentseva E.A., Harastani H., Raju S., Liu M., Schmidt A.G., Curiel D.T., Boon A.C, & Diamond M.S. (2024). Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. Nature Immunology, 25(3), 537-551.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!